Premier Research nabs Astellas, J&J cancer veteran for its oncology team


Biopharma cancer drug developer Cassandra Matney, M.D., has joined CRO Premier Research as its new senior medical director.

Matney has been poached by Premier from Astellas, where she was senior medical affairs liaison for the last two years, with a focus on uro-oncology and blood cancer, as well as former stints at J&J and Incyte.

But it’s not all been biopharma, and she returns to a CRO five years after working at Covance (now owned by LabCorp).

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

“Cassandra’s background as an M.D. at large global pharmaceutical firms enriches our existing oncology team and adds dimension to our insight and vision in this therapeutic area,” said Premier Research VP of medical affairs Teresa Nunes.

“She brings experience identifying and engaging investigators for clinical development and medical affairs and has broad oncology drug knowledge.”

“Unlike many contract research organizations, Premier Research delivers customized support, tailored to the small biotech companies that are the true innovators in drug development,” added Matney.

“However, many small biotechs lack the resources of large biopharmaceutical corporations, which I've seen firsthand going back to my initial position as a clinical research assistant. Working with Premier Research, I am excited I can now fully support these innovators throughout their clinical development programs.”

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.